SEC Form 4 · accession 0001140361-16-084233
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean Jacques Bienaime
Officer — Chief Executive Officer · Director
Period of report
Oct 27, 2016
Accepted (ET)
Oct 31, 2016 · 7:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 27, 2016 | M | 60,000 | $14.39 | A | 383,368 | D | |
| Common StockF1,F2 | Oct 27, 2016 | S | 60,000 | $81.3408 | D | 323,368 | D | |
| Common StockF1 | Oct 28, 2016 | M | 60,000 | $14.39 | A | 383,368 | D | |
| Common StockF1,F3 | Oct 28, 2016 | S | 60,000 | $81.2665 | D | 323,368 | D | |
| Common Stock | holding | — | — | — | 25,758 | I | Shares held by Bienaime Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy Common Stock)F1,F4 | $14.39 | Oct 27, 2016 | M | 60,000 | D | Nov 12, 2009 | May 11, 2019 | Common Stock | 60,000 | 177,000 | D |
| Stock Option (right to buy Common Stock)F1,F4 | $14.39 | Oct 28, 2016 | M | 60,000 | D | Nov 12, 2009 | May 11, 2019 | Common Stock | 60,000 | 117,000 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on June 9, 2016. Mr. Bienaime's former spouse will receive the net proceeds from the shares sold in this transaction in connection with cash payments owed to her pursuant to a marital separation agreement between her and Mr. Bienaime.
- F2The price in column 4 is the weighted average price. The price actually received ranged from $80.36 to $83.261. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- F3The price in column 4 is the weighted average price. The price actually received ranged from $79.20 to $82.45. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- F4Reflects the number of stock options outstanding after the transaction from this specific stock option grant.